By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Indivumed and Apceth today announced a partnership to develop technology that can predict patient response to targeted cellular or gene therapies in different cancer types.

The technology, which would allow patients to be stratified based on their response to therapies, would use Indivumed's analytical platform for cancer tissue in order to identify and validate protein biomarkers and targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.